Subscribe to the newsletterForward | Contact |   December 2014
12/10/2014 - Nosocomomial Infections Day

The 6th edition of the Nosocomial Infections day organized by Lyonbiopole and the Finovi Foundation was attended by 70 participants from the academic, hospital and industrial communities. After an opening on the simulation of the evolution for the analysis of bacterial resistance, the presentations were focused on innovative approaches for diagnosis, biosensors and biomarkers, new therapeutic approaches, and finally on biological engineering for therapeutic purposes or vaccine. Along with all of these presentations, the day also enabled different communities to interact and build relationships with the prospect of future collaborations.
Contact : Hugo Veysseyre, Innovation Project Manager -

11/28/2014 - Success for the 6th edition of the Lyonbiopole's Private Inv€stment Day

More than 120 participants were present at Lyonbiopole’s Private Inv€stment Day, organized in collaboration with Bpifrance, Pulsalys, Gate1, NOVACITE and KPMG and with the support of Sanofi-Pasteur. This event is a unique event for Entrepreneurs and investors in Life Sciences to meet and discuss. It was divided into 3 highlights. Starting by an investors’ breakfast that enabled 10 SMEs to present their project to a pannel of 28 investors. It was follow by 2 round tables, the first one on Due Diligence, a crucial step in the fund rising process and the second one dedicated to IPO. During the round tables, entrepreneurs, investors and investment professionals shared their experience and gave advice to the youngest one. A busy day that ended with a networking lunch.
Contact : Kevin Romani, SME's Development Director -

Alizé Pharma

Alizé Pharma is a Lyonbiopole company member, specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases. Alizé announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties. A new company, Alizé Pharma SAS III, was created to develop this project. It also announced this month, the completion of two Phase I clinical trials with its unacylated ghrelin analog AZP-531 in 76 healthy volunteers andoverweight or obese subjects.

Learn more

03/9-11/2015 - BIO Europe Sring Paris 2015

This event is considered as one of the major event of the biotechnology industry. It hosts over 2,000 participants, with no less than 11,000 appointments BtoB and over 1200 companies present. Exhibitors are also expected to present the latest innovations in the sector. BIO- Europe Spring will bring together more than 40 countries around meetings, wokshops, business presentations. Discover the detailed program here. A special offer is available to our members who want to participate in this convention.
Contact : Simon Gudin, SME's Development Project Manager -

Learn more

04/15-16/2015 - Registration opened for Investor Conference and Catalyzer of BIOVISION

Nominations for BIOVISION Catalyzer and BIOVISION Investor Conference are opened since 10th December. You have until February 28th, 2015 to file your application online. BIOVISION Catalyzer allows start-ups and collaborative projects to get exposure and promotes meetings of partners. BIOVISION Investor Conference provides an opportunity for companies in research funding to pitch to a panel of investors.
Contact : Hugo Veysseyre, Project Manager Innovation Clinic -

Learn more


BioEurope Spring 2015
From March, 9th to 11th, 2015 - Paris, France

2015 Annual Meeting of the HKS Inflammation and autoimmunity
From April 14th to 16th, 2015 - Annecy, France

Biovision 2015
From April 15th to 16th, 2015 - Lyon, France

Convention Internationale BIO 2015
From June 15th to 17th 2015 - Philadelphie, US

11/2014 - Eurostars : call for projects open 

Eurostars call for projects is open. This funding programme is fully dedicated to innovative SMEs aiming to launch R&D projects closed to the market, that are collaborative and European (at least 2 partners from EU). The funding rate for projects goes from 30 to 40% (subsidy managed by BPI France). The submission deadline is fixed on 03/5/2015. Lyonbiopole supports you to build up European projects.
Contact : Emilie Romeo, Europe Project Manager -

Learn more

12/2014 - EuroNanoMed II Transnational Call Open 

The EuroNanoMed II ERA-NET consortium launches its sixth call for projects to support innovative transnational projects in nanomedicine. The call topics are regenerative medicine, diagnostics and targeted delivery systems. Projects must gather at least 3 partners from 3 countries participating in the ERA-NET. Project leaders must register before 14/01 – the submission deadline is scheduled on 03.03.2015.
Contact : Emilie Romeo, Europe Project Manager -

Learn more

12/2014 - EDCTP2 launches its new calls for projects

The EDCTP initiative "European & Developping Countries Clinical Trials Partnerships" launches new calls for projects. This program aims to support the development of clinical trials between some European and African countries and third parties such as the Bill and Melinda Gates Foundation. Three families of calls can be financed: clinical trials, research grants and capacity building mainly for the fight against HIV / AIDS, malaria and tuberculosis. EDCTP2 includes infectious neglected diseases, all clinical phases will be possible and the diagnostic approach is integrated. A first call within the family "clinical trials" is launched the development of diagnostic tools for infectious diseases linked to poverty. Deadline : 03/02/2015.
Contact : Emilie Romeo, Europe Project Manager -

Learn more

11/2012 - H2020 SME instrument 

H2020 program includes the SME instrument. It targets the highly innovative SMEs with a strong ambition to develop, grow and internationalize; focusing on the delivery of new products, services or processes on the market. For SMEs in the health sector, the SME instrument is focused on the PHC-12 Clinical research for the validation of biomarkers and/or diagnostic medical devices line. The project can be presented by a single SME, and different phases depending on the maturity of the project. Next submission deadline: Phase 1 & 2 projects = 03/18/2015. Lyonbiopole supports you to build up European projects.
Contact : Emilie Romeo, European Project Manager - 

Learn more

12/2014 – IMI 2: calls for projects open 

IMI (Innovative Medicines Initiative) is a public-private partnership between the pharmaceutical groups, members of EFPIA and the European Union. Its aim is to financially support collaboration in the field of innovative medicines in order to increase security and efficiency. As part of IMI 2, 2 calls have just been launched: Call 3 (deadline on 03/24/2014) and Call 4 (deadline 02/11/2015). Find the call details here and the next dates of webinars. Lyonbiopole supports you to build up European projects.
Contact : Emilie Romeo, Europe Project Manager -

Learn more

12/19/2014 - Flogentec offers its new FLO400 to the biologic and genetic research

In 2011, Flogentec launched a new R&D project in order to give new Laboratory equipment for biological researches. Flo400 was born throughout a strong partnership between the company and the CNRS. Flo400 is the first appliance which automatize and robotize all the processes for In Situ Hybridization (ISH) and Immunohistochemestry (IHC). This allows the researchers and diagnostic department to progress efficiently about cancer and genetic topics. For all those workouts, Anthemis Technologies and Flogentec have been rewarded by the highest distinction: “2014 Innovation Trophy”.

Learn more

12/19/2014 - Adocia and Eli Lilly announce alliance

Eli Lilly and Company and Adocia announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. BioChaperone Lispro relies on Adocia’s proprietary BioChaperone® technology and is currently in Phase Ib studies.

Learn more

12/19/2014 - Innate Pharma, first Phase II trial of IPH2201

Innate Pharma announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charité Comprehensive Cancer Center (CCCC), Berlin - Germany. IPH2201-201 is an open label Phase II trial testing IPH2201 as a single agent in a preoperative setting of squamous cell carcinoma of the oral cavity, a tumor type representative of the larger group of squamous cell cancer of the head and neck.

Learn more

12/16/2014 - Eveon signing of an agreement with AAA

EVEON, designer and manufacturer of medical devices for the preparation and administration of medicinal products, has announced the signing of an agreement with Advanced Accelerator Applications (AAA), a European leader in the production and marketing of radiopharmaceutical products for PET (Positron emission tomography). AAA is a major name in personalised and nuclear medicine. The group is committed to the development of new therapeutic product candidates.

Learn more

12/12/2014 - Ecrins Therapeutics, new fundraising

Ecrin Therapeutics plan to quickly develop ET-D5 for the treatment of agressive cancers, such as tumors of kidney, pancreas, liver or sarcomas. The 1st clinical trial has been already programmed for the begining 2016 at the Centre Léon Bérard (Lyon). We are raising 500 K€ in order to complete the last steps leading to clinicals trials, namely regulatory toxicology studies.

Learn more

12/11/2014 - Valneva and BliNK announce launch of new biotech company in innovative antibody discovery

European biotechnology company Valneva SE and UK company BliNK Therapeutics Ltd (“BliNK Therapeutics”) announced  the creation of a private company specialized in the discovery of innovative monoclonal antibodies to be headquartered in Lyon, France and to be named BliNK Biomedical SAS. The new company, which will benefit from the combination of two validated antibody discovery platforms, BliNK therapeutics Ltd’s IVV and Valneva’s VIVA|Screen®, has already secured its first round of financing.

Learn more

12/11/2014 - The EIT Health KIC (Innolife Consortium) wins the EIT call for projects

The InnoLife consortium has been selected by the European Institute of Innovation and Technology (EIT) to constitute the EIT Health community. This initiative will start in 2015 with term funding of € 80 million per year for training, innovation and industry projects around the healthy ageing and autonomy topics. This community includes six co-location centers in Barcelona (Spain), Heidelberg (Germany), London (UK / Ireland), Rotterdam (Belgium-Netherlands), Stockholm (Scandinavia) and the French site with anchor in Ile de-France and Rhône-Alpes. Many French players in research, education, industry and innovation (including several clusters as Lyonbiopole) were stakeholders in the project application in September.
Contact : Emilie Roméo, European Projects Manager -

Learn more

12/10/2014 - ImmunID: PREDICT-ID clinical trial

ImmunID, an immune molecular diagnostics company, announced that the ethic committee and regulatory bodies have granted authorizations to start its PREDICT-ID Melanoma study to assess the predictive value of immune profiles for response to Ipilimumab®, an immunomodulatory agent approved in more than 40 countries.

Learn more

12/08/2014 - Erytech Pharma, GRASPA®, Phase III

ERYTECH reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia. Positive top-line data of the study were made available end of September, and demonstrated that the Phase III GRASPIVOTALL clinical trial met both of its primary endpoints.

Learn more

12/04/2014 - Bio Elpida inauguration

Bio Elpida, supported by the city of Saint-Priest - represented by the Mayor, Gilles Gascon - and many representatives from the Lyon Métropole, inaugurated its new premises at the heart of the city’s technology park on Thursday 4th December. It afforded the opportunity for its founders to restate the potential for great medical advances of tomorrow to be developed in the heart of laboratories like Bio Elpida.

Learn more

12/02/2014 - GeNeuro and Servier sign partnership

GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced that it has entered into a strategic partnership with Servier, the leading independent French pharmaceutical company, to develop and market GNbAC1 in Multiple Sclerosis (MS). As the first drug addressing a causal factor of the disease, GNbAC1 has the potential to radically change the way MS patients are treated.

Learn more

12/02/2014 - Eveon awarded 1st prize Invent Tomorrow

Eveon, designer and manufacturer of medical devices used in the preparation and/or administration of medication, was awarded the 1st prize Monday evening in the Inventer Demain competition after winning the vote of an expert jury and the audience. Jointly organised by France 3 and RTS (Radio Télévision Suisse), this competition brought together 60 pre-selected companies.

Learn more

© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |